摘要
This study aims to evaluate the long-term therapeutic efficacy and safety of AAV-mediated hfCas12Max-ATXN3 gRNA DNA editing in neonatal and adult humanized SCA3 mouse models.
Design and screen guide RNAs (gRNAs) targeting the human ATXN3 gene, and construct and package AAV vectors. Using humanized YACMJD84.2Q-C57BL/6 homozygous SCA3 mice (hereinafter referred to as 84Q/84Q mice) as the model, low-dose (neonates: 5.0×10^10 vg/mouse; adults: 2.5×10^11 vg/mouse) and high-dose (neonates: 1.0×10^11 vg/mouse; adults: 5.0×10^11 vg/mouse) AAV-hfCas12Max-ATXN3 gRNA interventions were administered via intracisternal magnal injection (ICM) during neonatal (P0-1) and adult (3 months of age) stages of the model mice. The viral distribution (copy number) in key brain regions was detected using absolute quantitative polymerase chain reaction (PCR); the frequency of ATXN3 gene insertions/deletions (indels) was assessed by next-generation sequencing (NGS); protein expression was analyzed via Western blot (WB) and immunofluorescence (IF) assays; motor function in model mice was evaluated through behavioral experiments; serum biochemical parameters and neurofilament light chain (NfL) levels were measured; and safety was evaluated via multi-organ histopathological examination.
1. In vitro screening showed that gRNA4 and gRNA11 effectively targeted the ATXN3 gene and induced significant indel effects (gRNA4: 41.41% ± 1.49%, gRNA11: 40.13% ± 0.27%).
2. In neonatal 84Q/84Q mice, the system efficiently targeted the cerebellum and brainstem, with a reduction in mutant protein expression and aggregation observed within one month (P<0.05). After 6 months, the viral vector continued to express stably in the brain, maintaining gene editing efficiency and long-term suppression of mutant protein expression. Neuroinflammation was reduced, Purkinje cell loss was rescued, and motor function was significantly improved (P<0.05).
3. In adult 84Q/84Q mice, treatment after 3 months resulted in efficient delivery and editing of both low and high doses, with a significant reduction in mutant protein expression (P<0.05). However, no significant difference was found in HMW aggregate levels. There were no significant changes in body weight, length, or width compared to the untreated group. Balance coordination and fatigue rotarod tests showed significant recovery in both the low- and high-dose groups (P<0.05), while open-field activity remained unchanged. Histological analysis revealed reduced astrocyte proliferation, increased Purkinje cell survival, and restored NfL levels (P<0.05).
4. In adult wild-type mice, high-dose treatment did not induce motor dysfunction or abnormal changes in ALT, AST, BUN, or histopathological structure in the brain, liver, or kidney.
The AAV-hfCas12Max-ATXN3 gRNA gene editing system provides a durable, specific, and safe therapeutic strategy that significantly improves motor function and delays neurodegenerative changes in the SCA3 mouse model.
